Worldwide: $519 Million FCPA Payment By Teva Pharmaceuticals—Largest Ever FCPA Payment By Pharmaceutical Company—Follows Large FCPA Plea Agreement With Obedrecht And Braskem


On December 22, 2016, the world's largest manufacturer of generic pharmaceuticals, Teva Pharmaceuticals ("Teva"), agreed to pay $519 million in FCPA-related criminal penalties, disgorgement, and interest. The Israeli company Teva entered into a deferred prosecution agreement with the U.S. Department of Justice ("DOJ") to settle allegations that it had bribed government officials in Russia, Ukraine, and Mexico. Teva's settlement is the fourth-largest Foreign Corrupt Practices Act ("FCPA") settlement ever, and the largest-ever by a pharmaceutical company. The $519 million payment imposed on Teva is significantly higher than the next-highest FCPA-related payment imposed on a pharmaceutical company, $70 million imposed in 2011.

The Teva settlement came on the heels of Odebrecht and Braskem's global $3.5 billion settlement with authorities in the United States, Brazil, and Switzerland, announced the day before, on December 21, 2016. The Brazilian-based construction company Odebrecht pleaded guilty to a conspiracy to violate the FCPA, with the fine to be determined in the future at sentencing on April 17, 2017. Braskem, Odebrecht's petrochemical unit, also pleaded guilty.

Teva: Bribes to Government Officials and Inadequate Internal Controls

The Teva agreement detailed the company's payment of bribes to government officials in Russia, Ukraine, and Mexico, and the company's lack of internal controls to prevent bribery.

In Russia, Teva executives and employees bribed a high-ranking government official in order to increase sales of Teva's multiple sclerosis drug Copaxone, one of Teva's most profitable products. The Russian government official influenced the Russian Ministry of Health's annual drug purchase auctions to increase Copaxone sales. In return, Teva employed the Russian government official's drug repackaging and distribution company. From 2010 until at least 2012, he earned approximately $65 million through inflated profit margins to his company.

In Ukraine, Teva also bribed a senior Ukrainian Ministry of Health official to influence Ukraine's approval of Teva's drug registrations, including those of Copaxone and insulins. These drug registrations were necessary to market and sell products within Ukraine. From 2001 to 2011, Teva employed the official as a "registration consultant," paying him a monthly fee along with other items of value, including travel, totaling approximately $200,000.

In Mexico, Teva's Mexican subsidiary bribed doctors starting in at least 2005 to prescribe Copaxone. Teva became aware of these bribes in 2009, when the company was developing its anti-corruption compliance program. Despite this awareness, Teva approved and implemented an anti-bribery compliance program that could neither prevent nor detect bribes. Additionally, compliance managers were put in place who either could not or would not enforce Teva's anti-corruption policies.

Teva: Deferred Prosecution Agreement Accounts for "Substantial Cooperation and Remediation"

The U.S. government's investigation of Teva began in 2012 with a U.S. Securities and Exchange Commission ("SEC") subpoena. Teva learned of its FCPA problems that same year, and immediately took steps to address the problems. In 2012, Teva voluntarily began a comprehensive investigation into its global operations and named a global head of compliance. Teva engaged independent counsel to conduct a global corruption risk assessment. In 2013, Teva replaced its entire Russian leadership team. Teva no longer employs the individuals involved in the bribes.

On December 22, 2016, Teva entered into a deferred prosecution agreement ("DPA") with the DOJ, agreeing to pay criminal penalties of approximately $283 million. The DPA requires that Teva work with an independent compliance monitor for three years. Teva also agreed to pay the SEC approximately $236 million in disgorgement and pre-judgment interest. The DOJ charged the company with two counts: one of conspiracy to violate the FCPA and one of failing to implement adequate internal controls. Teva Russia pleaded guilty to one count of conspiracy to violate the FCPA.

Teva's remediation efforts were noted by the DOJ, including (1) terminating employees, (2) enhancing compliance, (3) improving anti-corruption training, (4) adopting a stand-alone third-party due diligence program, (5) making Teva's control functions more independent and establishing an office to address reports of misconduct, and (6) strengthening the internal audit and investigations teams.

While the DOJ reduced Teva's criminal penalty by 20% from the bottom of sentencing guidelines because of "substantial cooperation and remediation," Teva did not get the largest possible reduction due to actions that delayed the government's investigation, including "overbroad assertions of attorney-client privilege" and slow responses to document requests. Additionally, Teva did not get any credit for self-disclosing.

Odebrecht & Braskem: Bribery of Politicians and Political Parties

The December 21, 2016 settlement with Odebrecht and Braskem was part of "Operation Car Wash," a long-running investigation by Brazil prosecutors into corruption at Petrobras, Brazil's state energy company. Earlier in 2016, Odebrecht's CEO had been sentenced to 19 years imprisonment.

Odebrecht admitted to a bribery and bid-rigging scheme that started as early as 2001, through which the company paid approximately $788 million in bribes to government officials and political parties in many countries. The bribes were directed by company management and were paid using shell companies, off-shore bank accounts, and off-book transactions. A dedicated department within Odebrecht, the "Division of Structured Operations," administered these bribes. The Division of Structured Operations had an entirely separate off-books communications system that allowed communication using codenames and passwords via secure emails and instant messages.

As Odebrecht's petrochemical unit, Braskem contributed about $250 million to Odebrecht's bribe system. This money ended up with Brazilian politicians and political parties, as well as with a Petrobras official. In exchange, Braskem received benefits that included contracts with Petrobras, preferential rates for the purchase of Petrobras' raw materials, and favorable legislation reducing Braskem's Brazil tax liabilities.

On December 21, 2016, Odebrecht and Braskem settled with the DOJ, Brazil's Ministerio Publico Federal, and Switzerland's Office of the Attorney General. The plea agreements require that the companies employ an independent compliance monitor for three years. The agreements accounted for the companies' failure to voluntarily disclose; the nature and seriousness of the offenses, which involved the highest levels of the companies, lasted many years, and occurred in multiple countries; and the lack of an effective compliance and ethics program at the time of the offenses.

Odebrecht agreed that the appropriate criminal penalty would be $4.5 billion, but the company has claimed it can only pay $2.6 billion. The penalty will be determined during sentencing on April 17, 2017. Eighty percent of Odebrecht's penalty will go to Brazil, with the United States and Switzerland each receiving 10 percent. Braskem pled guilty to one count of conspiring to violate the FCPA, agreeing to pay a $632 million criminal penalty. Braskem settled related charges with the SEC, agreeing to pay $325 million in disgorgement of profits. Seventy percent of Braskem's penalty will go to Brazil, with the United States and Switzerland each receiving 15 percent. Between the penalties and the disgorgement, the United States will receive approximately $94.8 million from Braskem.

The companies' remediation efforts were noted by the DOJ, including (1) disciplining and terminating employees, (2) heightening controls and compliance programs, and (3) "significantly increasing" compliance resources.

Odebrecht's penalties were reduced by 25 percent from the bottom of sentencing guidelines as a result of Odebrecht's "full cooperation," and Braskem's penalties were reduced by 15 percent from the bottom of sentencing guidelines as a result of Braskem's "partial cooperation."


With the Odebrecht, Braskem, and Teva payments, U.S. authorities will have imposed a record-setting $2.15 billion in FCPA-related payments in 2016, greatly exceeding the previous annual record for FCPA-related payments of $1.6 billion set in 2014. None of the companies voluntarily self-disclosed, and the U.S. government insisted that all three employ independent compliance monitors for three years. These settlements show that companies must cooperate promptly and completely in order to receive full financial credit for cooperation.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions